Callan Family Office’s Madrigal Pharmaceuticals MDGL Stock Holding History

Callan Family Office’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-366	Closed	-$213K	–	1160
2025 Q4	$213K	Buy	+366	New	+$187K	﹤0.01%	1042

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Callan Family Office's MDGL Position: Q1 2026 in Review

Callan Family Office sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 366 shares — an estimated $213K sold.

Callan Family Office first reported a position in MDGL in Q4 2025 and held it in 1 quarter. The position peaked at $213K in Q4 2025. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Callan Family Office reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Callan Family Office sold 366 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $213K.
Callan Family Office first reported a position in Madrigal Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Callan Family Office's Madrigal Pharmaceuticals position peaked at $213K in Q4 2025.
380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.